Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 133 citing articles:

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 992
A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
Josh Reed, Stephen C. Bain, Venkateswarlu Kanamarlapudi
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 3567-3602
Open Access | Times Cited: 295
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Jae‐Seung Yun, Seung‐Hyun Ko
Metabolism (2021) Vol. 123, pp. 154838-154838
Open Access | Times Cited: 181
2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association
Cheryl Bushnell, Walter N. Kernan, Anjail Sharrief, et al.
Stroke (2024) Vol. 55, Iss. 12
Closed Access | Times Cited: 37
Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
Maria‐Ioanna Stefanou, Aikaterini Theodorou, Konark Malhotra, et al.
European Stroke Journal (2024) Vol. 9, Iss. 3, pp. 530-539
Open Access | Times Cited: 20
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
Nikolaus Marx, Melanie J. Davies, Peter J. Grant, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 9, Iss. 1, pp. 46-52
Open Access | Times Cited: 131
Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics
Therese S. Salameh, Elizabeth M. Rhea, Konrad Talbot, et al.
Biochemical Pharmacology (2020) Vol. 180, pp. 114187-114187
Open Access | Times Cited: 106
Role of coronary artery calcium score in the primary prevention of cardiovascular disease
Khurram Nasir, Miguel Cainzos‐Achirica
BMJ (2021), pp. n776-n776
Closed Access | Times Cited: 103
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
Michael A. Nauck, Daniel R. Quast
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 69
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 53
Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists
Ronald Goldenberg, Alice Cheng, Tess Fitzpatrick, et al.
Stroke (2022) Vol. 53, Iss. 5, pp. 1813-1822
Open Access | Times Cited: 40
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
Sara Piccini, Giuseppe Favacchio, Cristina Panico, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 28
Secondary Ischemic Stroke Prevention
Aaron Bangad, Mehdi Abbasi, Adam de Havenon
Neurotherapeutics (2023) Vol. 20, Iss. 3, pp. 721-731
Open Access | Times Cited: 27
Imeglimin prevents heart failure with preserved ejection fraction by recovering the impaired unfolded protein response in mice subjected to cardiometabolic stress
Hiroki Kitakata, Jin Endo, Shun Hashimoto, et al.
Biochemical and Biophysical Research Communications (2021) Vol. 572, pp. 185-190
Open Access | Times Cited: 52
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
Andrea Natali, Lorenzo Nesti, Domenico Tricò, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 44
How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4651-4651
Open Access | Times Cited: 30
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 41
Meta-analysis of type 1 diabetes mellitus and risk of cardiovascular disease
Xingming Cai, Jiayong Li, Wenting Cai, et al.
Journal of Diabetes and its Complications (2021) Vol. 35, Iss. 4, pp. 107833-107833
Closed Access | Times Cited: 35
Metabolic Impact of Frailty Changes Diabetes Trajectory
Alan J. Sinclair, Ahmed H. Abdelhafiz
Metabolites (2023) Vol. 13, Iss. 2, pp. 295-295
Open Access | Times Cited: 16
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review
Katherine Young, Eram Haider McInnes, Robert Massey, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 14
Effects of glucagon‐like peptide‐1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials
Paschalis Karakasis, Theocharis Koufakis, Dimitrios Patoulias, et al.
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 5
Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
Young‐Gyun Seo
Journal of Obesity & Metabolic Syndrome (2020) Vol. 30, Iss. 1, pp. 12-19
Open Access | Times Cited: 34
Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
Chen-Yi Yang, Ying-Ren Chen, Huang‐Tz Ou, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 30
The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
Bertram Pitt, Philippe Gabríel Steg, Lawrence A. Leiter, et al.
Cardiovascular Drugs and Therapy (2021) Vol. 36, Iss. 3, pp. 561-567
Open Access | Times Cited: 30
Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
Jiejin Zhu, Ying Zhou, Qingyu Li, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4216-4235
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top